A Study of MGC030 in Participants With Advanced Solid Tumors

The study is designed to characterize safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary anti-tumor activity of MGC030. Participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors of select types. The main question the study aims to answer is: * What types of side effects will participants experience when receiving MGC030? * Can MGC030 cause cancer to shrink, remain stable, or able to control disease progression of participants with advanced solid tumors? Participants will * Undergo screening procedures to determine eligibilit

Trial Details

NCT ID
NCT07822399
Phase
PHASE1
Sponsor
MacroGenics
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • MGC030
Locations (sample)
  • Lake Success, New York, United States|40.77066,-73.71763

Key Eligibility Criteria

  • Participants in dose escalation cohorts must have histologically proven unresectable, locally advanced or metastatic solid tumor limited to one of …
  • Participants in expansion cohorts must have histologically proven, unresectable, locally advanced or metastatic solid tumors
  • Urothelial cancer with progression following platinum-containing chemotherapy for metastatic or locally advanced/unresectable cancer, or within 12 …
  • Gastric/GEJ carcinoma with progression during or following at least 1 systemic therapy.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →